Navigation Links
Len DeBenedictis Retires as Chief Technology Officer of Solta Medical, Inc.
Date:9/15/2010

HAYWARD, Calif., Sept. 15 /PRNewswire-FirstCall/ -- Solta Medical, Inc. (Nasdaq: SLTM), a global leader in the medical aesthetics market, today announced that Leonard C. DeBenedictis, 69, Chief Technology Officer and a member of the company's board of directors, will retire from Solta Medical on October 1, 2010. Mr. DeBenedictis will be available to advise the company through the end of the year and he plans to remain active in the development of other emerging medical technologies.

Stephen J. Fanning, Chairman of the Board, President and CEO of Solta Medical, Inc. said, "Len has dedicated more than 45 years to the evolution of the laser industry and for the past decade was the driving force behind the breakthrough proprietary technology in our Fraxel® family of lasers. He joined us in 2008 with our acquisition of Reliant Technologies where Len was co-founder and CTO. In his tenure at Solta Medical, Len's leadership resulted in Solta's flagship product for fractional skin resurfacing, the Fraxel re:store® DUAL. In addition, Len has been a key player in forging our personal care product initiative with Philips Consumer Lifestyle and leaves us with an impressive pipeline of innovative products. I want to thank him for all of his contributions to the company."

About Solta Medical, Inc.

Solta Medical, Inc. is a global leader in the medical aesthetics market providing innovative, safe, and effective solutions for patients that enhance and expand the practice of medical aesthetics for physicians. The company offers products to address a range of skin issues under the industry's three premier brands: Thermage®, Fraxel® and Isolaz®. Thermage is an innovative, non-invasive radiofrequency procedure for tightening and contouring skin. As the leader in fractional laser technology, Fraxel delivers minimally invasive clinical solutions to resurface aging and sun damaged skin. Isolaz is the only laser or light based system indicated for the treatment of inflammatory acne, comedonal acne, pustular acne, and mild-to-moderate inflammatory acne. Since 2002, approximately one million Thermage, Fraxel and Isolaz procedures have been performed in over 100 countries. For more information about Solta Medical, call 1-877-782-2286 or log on to www.Solta.com.


'/>"/>
SOURCE Solta Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. RetireSafe Announces Intention to Key Vote Senator Dorgans Drug Importation Amendment (SA 2793)
2. RetireSafe Urges Senate to Defeat Senate Amendment 2793 -- Says Senator Dorgans Drug Importation Plan Puts Seniors at Risk
3. AAIPharma Services Corp. Names Patrick Walsh Chief Executive Officer
4. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
5. ERT Announces Upcoming Retirement of Michael McKelvey as Chief Executive Officer
6. Mindray Appoints Mr. Minghe Cheng as Chief Strategic Officer
7. SL Industries Names Louis J. Belardi Chief Financial Officer
8. Mark S. Rangell Appointed Chief Operating Officer for Sandata Technologies, LLC
9. Former Singapore EDB Officer, Chew Hwee Yong, Joins Menicon as Chief of Special Projects as Menicon Accelerates its Globalization
10. Kendle Appoints Mark J. Roseman, D.Sc., Senior Vice President and Chief Marketing Officer
11. Millennium Laboratories Announces New Chief Operating Officer David Cohen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... 2016 - Revenue Forecasts ... Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine ... New Study Reveals Selling Opportunities and Revenue Prospects ... ,What is the future of biologics, especially new ... commercial analysis. Staying ahead in data and knowledge, ...
(Date:5/19/2016)... Calif. , May 19, 2016  According ... thirds of the world lacks basic diagnostic imaging. ... in the United States , ... to such technology. In fact, the WHO reports ... risk of avoidable or treatable death, simply due ...
(Date:5/19/2016)... According to a new market research report "Sunitinib Malate ... Germany , France , U.K., ... Japan )", published by MarketsandMarkets, The market is projected to ... from 2016 to 2021.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302 ... through 26 Pages and in-depth TOC on "Sunitinib Malate ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... NutraPre today announced the ... pregnant women to prevent morning sickness and promote overall heath. Engineered with advanced ... and taste of water. , “Imagine a pregnancy without morning sickness,” NutraPre CEO ...
(Date:5/23/2016)... Angeles, CA (PRWEB) , ... May 23, 2016 , ... ... surgeons have noted that, less than 1% of United Kingdom residents who could benefit ... UK’s National Health Service (NHS) increases the number of bariatric procedures it offers to ...
(Date:5/23/2016)... ... , ... NYDNRehab, a New York City-based physical therapy clinic , is ... this type of technology, which was developed by world-renowned researcher Dr. Christopher Powers of ... , With over 10 million sport injuries per year in the United ...
(Date:5/23/2016)... ... May 23, 2016 , ... The Society for Women’s Health ... to move on from that role. , “No one in Washington led the way ... said SWHR Founder Florence Haseltine, MD, PhD. “We offer our deep gratitude to Phyllis ...
(Date:5/23/2016)... , ... May 23, 2016 , ... ... care to residents of Westchester County for over 24 years, recently hosted its ... community members joined HOW for two remembrance ceremonies, each concluding with the release ...
Breaking Medicine News(10 mins):